Celldex Therapeutics, Inc. (CLDX)
39.42
+0.18
(+0.46%)
USD |
NASDAQ |
Sep 02, 10:41
Celldex Therapeutics Debt to Equity Ratio : 0.0069 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0069 |
| March 31, 2026 | 0.0042 |
| December 31, 2025 | 0.0044 |
| September 30, 2025 | 0.0044 |
| June 30, 2025 | 0.0046 |
| March 31, 2025 | 0.0049 |
| December 31, 2024 | 0.0051 |
| September 30, 2024 | 0.0039 |
| June 30, 2024 | 0.0029 |
| March 31, 2024 | 0.0025 |
| December 31, 2023 | 0.0059 |
| September 30, 2023 | 0.0115 |
| June 30, 2023 | 0.0117 |
| March 31, 2023 | 0.0121 |
| December 31, 2022 | 0.0124 |
| September 30, 2022 | 0.0105 |
| June 30, 2022 | 0.011 |
| March 31, 2022 | 0.0066 |
| December 31, 2021 | 0.0073 |
| September 30, 2021 | 0.0071 |
| June 30, 2021 | 0.0152 |
| March 31, 2021 | 0.0162 |
| December 31, 2020 | 0.0166 |
| September 30, 2020 | 0.0166 |
| June 30, 2020 | 0.0127 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0453 |
| December 31, 2019 | 0.0389 |
| September 30, 2019 | 0.0368 |
| June 30, 2019 | 0.0402 |
| March 31, 2019 | 0.0464 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Gilead Sciences, Inc. | 2.219 |
| Ionis Pharmaceuticals, Inc. | 4.978 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 782.35M |
| Total Liabilities (Quarterly) | 67.78M |
| Shareholders Equity (Quarterly) | 714.56M |
| Current Ratio | 11.82 |
| Net Debt Paydown Yield | -0.01% |